Lux Receives Fast Track Status for Transplant Rejection Drug
Posted on: Friday, 1 February 2008, 12:00 CST
Lux Biosciences has reported that the FDA has granted Fast Track designation for LX201, a silicone matrix ocular implant that steadily releases therapeutic doses of cyclosporine A locally to the eye, to prevent corneal transplant rejection.
The Fast Track drug development program is designed to promote the development of drugs to treat life-threatening or very serious conditions and requires that the drug demonstrate the potential to address unmet medical needs.
Ulrich Grau, president and CEO of Lux, said: "With this Fast Track designation, we can more rapidly work to provide a much needed therapy to patients. If successful, LX201 would become the first treatment available for the prevention of corneal transplant rejection."
Source: Datamonitor
Related Articles
- Blair Vows to Bring Bombers to Justice and Fast-Tracks New Laws Totackle the Terrorists
- John Paul Put on Fast Track for Sainthood
- FDA Gives Fast-Track Designation to Sarcoma Drug
- ARIAD Receives Fast-Track Designation By the FDA for mTOR Inhibitor, AP23573, in the Treatment of Sarcoma
- Rejuvenon's RC-1291 Ghrelin Mimetic Receives Fast Track Designation From FDA for Cancer Anorexia/Cachexia
- Panacos Gets Fast-Track Status for Drug
- CuraGen Receives Fast Track Designation for CG53135
- Phytopharm Plc Fast Track Designation Granted By the FDA for ALS Drug Candidate Myogane
- Phytopharm Plc; Fast Track Designation Granted By the FDA for ALS Drug Candidate Myogane
- FDA Grants Marshall Edwards, Inc. Fast-Track Designation for Phenoxodiol for Recurrent Ovarian Cancer
 |
 |
User Comments (0)
RSS Feeds